Table 1.
Data | RA | CG | p |
---|---|---|---|
Sample n (%) | 140 | 40 | 0.0657 |
Female | 130 (92.8%) | 33 (82.5%) | |
Male | 10 (7.2%) | 7 (17.5%) | |
| |||
Age in years, mean ± SEM | 54.0 (±12.0) | 51.5 (±8.5) | 0,0943 |
Race and ethnicity classifications | |||
Indigenous | 1 | 0 | ns |
Multiracial | 49 | 9 | ns |
Black or African American | 60 | 22 | ns |
White | 30 | 9 | ns |
| |||
Disease duration, years, mean ± SEM | 10.0 (±7.8) | ||
+ rheumatoid factor (n%) | 113 (80.7%) | ||
ESR mm/h, median, (range) | 36 (2–125) | ||
Disease classification (n%) | |||
CDAI, mean ± SEM | 18.5 (±13.0) | ||
Low disease activity (≤10) | 45 (32%) | ||
Moderate and high disease activity (>10) | 95 (68%) | ||
DAS28 mean ± SEM | 4.5 (±1.5) | ||
Low disease activity (≤3.2) | 31 (22.2%) | ||
Moderate and high disease activity (>3.2) | 109 (77.8%) | ||
| |||
Treatment (n) | |||
None (naïve for treatment) | 60 | ||
Prednisone only | 11 | ||
Methotrexate only | 12 | ||
Leflunomide only | 7 | ||
More than one treatment | 50 | ||
| |||
Comorbidities (n) | |||
None | 109 | ||
Diabetes mellitus | 9 | ||
Obesity | 6 | ||
Osteoporosis | 12 | ||
Systemic arterial hypertension | 24 |
CG- control group; SEM- standard error of mean; ESR- erythrocyte sedimentation rate.